Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?

Lethal effect of the anti-Fas antibody in mice

1993 • 1,915 citations

Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule

1994 • 1,120 citations

Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.

1993 • 643 citations

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

1997 • 403 citations

Fas Ligand Expression in Glioblastoma Cell Lines and Primary Astrocytic Brain Tumors

1997 • 153 citations

Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.

1996 • 142 citations

Fas/APO-1 gene transfer for human malignant glioma.

1995 • 127 citations

Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?

1995 • 110 citations

Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics

1997 • 96 citations

Expression of Fas/APO-1 during the progression of astrocytomas.

1995 • 96 citations

CD95 Ligand: Lethal Weapon Against Malignant Glioma?

1998 • 83 citations

Fas expression on human fetal astrocytes without susceptibility to fas-mediated cytotoxicity

1998 • 79 citations

Increased serum levels of soluble CD95 (APO‐1/Fas) in relapsing‐remitting multiple sclerosis

1998 • 72 citations

Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis

1998 • 58 citations

CD95-Dependent T-Cell Killing by Glioma Cells Expressing CD95 Ligand: More on Tumor Immune Escape, the CD95 Counterattack, and the Immune Privilege of the Brain

1997 • 38 citations